Crinetics Pharmaceuticals, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

Form 10-K

(Mark One)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2025

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to

Commission File Number:001-38583

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code:(858)450-6464

Securities registered pursuant to Section 12(b) of the Act:

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x Noo

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yeso No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x Noo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x Noo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. x

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. o

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yeso Nox

As of June 30, 2025 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $2.7 billion, based on the closing price of the registrant’s common stock on the Nasdaq Global Select Market on such date of $28.76 per share.

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of February 13, 2026 was 104,705,330.

DOCUMENTS INCORPORATED BY REFERENCE

Certain sections of the registrant’s definitive proxy statement for the 2026 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K.

GLOSSARY OF DEFINED TERMS

Unless expressly indicated or the context requires otherwise, the terms “Crinetics,” “Company,” “we,” “us,” and “our,” in this Annual Report on Form 10-K (this “Report”) refer to Crinetics Pharmaceuticals, Inc., a Delaware corporation, and, where appropriate, its wholly-owned subsidiaries. We also have used several other terms in this Report, most of which are explained or defined below.

“2024 Sales Agreement”means the Sales Agreement by and between Crinetics and the Sales Agents, dated June 21, 2024.

“A4”means androstenedione.

“ASD”means acromegaly symptom diary.

“ACTH”means the adrenocorticotrophic hormone.

“ADCS”means ACTH-Dependent Cushing’s Syndrome.

“AMP” means average manufacturer price.

“ANDA” means abbreviated new drug application.

“Bayh-Dole Act” means the Bayh-Dole Act of 1980.

“CAH” means congenital adrenal hyperplasia.

“CAPL”means Crinetics Australia Pty Ltd, our wholly-owned subsidiary.

“CCPA”means the California Consumer Privacy Act.

“cGMP” means current Good Manufacturing Practice.

“CHMP” means the Committee for Medicinal Products for Human Use.

“CIO” means Chief Information Officer.

“CJEU” means the Court of Justice of the European Union.

“CMS” means the Centers for Medicare & Medicaid Services.

“CPRA”means the California Privacy Rights Act.

“CRF1”means corticotropin-releasing factor type 1.

“CRL” means a Complete Letter Response.

“CMOs” means contract manufacturing organizations.

“CROs” means contract research organizations.

“CS” means carcinoid syndrome.

“EC” means the European Commission.

“EEA” means the European Economic Area.

“EMA” means the European Medicines Agency.

“ESPP” means our 2018 Employee Stock Purchase Plan.

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.

“EU CTR”means the EU Clinical Trials Regulation.

“EU-U.S. DPF”means the Trans-Atlantic Data Privacy Framework.

“FDA” means the U.S. Food and Drug Administration.

“FDCA” means the federal Food, Drug, and Cosmetic Act.

“FDIC” means the Federal Deposit Insurance Corporation.

“GC”means glucocorticoid.

“GCP”means good clinical practice.

“GDPR”means the General Data Protection Regulation.

i

“GEP”means gastroenteropancreatic.

“GEP-NETs”means gastroenteropancreatic neuroendocrine tumors.

“GH”means growth hormone.

“GHRA”means growth hormone receptor antagonist.

“GPCRs”means G protein coupled receptors.

“Hatch-Waxman Amendments”means the Drug Price Competition and Patent Term Restoration Act of 1984.

“HC”means hydrocortisone.

“HIPAA”means the federal Health Insurance Portability and Accountability Act of 1996.

“IGF-1” means growth factor-1.

“IND” means Investigational New Drug.

“IPR” means inter partes review.

“IRA” means the Inflation Reduction Act of 2022.

“IRBs” means institutional review boards.

“IRP” means the International Recognition Procedure.

“Loyal”means Cellular Longevity Inc., doing business as Loyal.

“Loyal License” means the license agreement entered into with Loyal on March 24, 2023.

“MAA” means marketing authorization application.

“MHRA” means the United Kingdom Medicines and Healthcare products Regulatory Agency.

“MMAE” means monomethyl auristatin E.

“Nasdaq” means the Nasdaq Global Select Market.

“NDA” means new drug application.

“NDC” means nonpeptide drug conjugate.

“NECs” means neuroendocrine carcinomas.

“NENs” means neuroendocrine neoplasms.

“NETs” means neuroendocrine tumors.

“NIDDK” means the National Institute of Diabetes and Digestive and Kidney Diseases.

“NIH” means the National Institutes of Health.

“OLE” means open-label extension.

“ODD” means Orphan Drug Designation.

“PALSONIFYTM®” means paltusotine for treatment of acromegaly in the U.S.

“PDUFA” means the Prescription Drug User Fee Act.

“PFS”means progression-free survival.

“PGR” means post-grant review.

“PK” means pharmacokinetics.

“PREA” means the Pediatric Research Equity Act.

“Privacy Shield” means the EU-US Privacy Shield Framework.

“PRRT” means peptide receptor radionuclide therapy.

“R&D” means research and development.

“Radionetics” means Radionetics Oncology, Inc.

ii

“Radionetics License” means the collaboration and license agreement entered into with Radionetics in October 2021.

“REMS” means risk evaluation and mitigation strategy.

“Sales Agents”means SVB Leerink LLC and Cantor Fitzgerald & Co.

“SKK” means Sanwa Kagaku Kenkyusho Co., Ltd.

“SKK Clinical Supply Agreement” means the clinical supply agreement entered into with SKK on June 14, 2022.

“SKK License” means the license agreement entered into with SKK on February 25, 2022.

“SBIR Grants” means Small Business Innovation Research Grants.

“SCCs” means standard contractual clauses.

“SCLC” means small-cell lung cancer.

“SRLs” means somatostatin receptor ligands.

“SST2” means the somatostatin receptor type 2.

“SSAs” means the somatostatin analogs.

“SEC” means the Securities and Exchange Commission.

“TED” means Thyroid Eye Disease.

“ULN” means the upper limit of normal.

“UPC” means the Unitary Patent Court.

“U.S.” means United States.

“U.S. GAAP” means U.S. Generally Accepted Accounting Principles.

iii